Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis. Dermatol Reports [Internet]. 2024 Aug. 9 [cited 2025 Jun. 19];17(1). Available from: https://journals.pagepress.org/dr/article/view/9999